Originally Aired: October 20, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
The robustness, flexibility, and adaptability of Chinese hamster ovary (CHO) cells have made them the “go-to” system for the stable production of a plethora of therapeutic proteins. These protein products include monoclonal antibodies and more complex architectures, such as multi-specifics or fusion polypeptides commonly used in drug development. Biopharmaceutical companies are always looking at increasing the robustness of their manufacturing processes to achieve adequate product yields while controlling their quality.
This drive has resulted in organizations using the same expression systems in their discovery activities that they will utilize later during cell line development (CLD) and clinical manufacturing. This approach has several benefits: on the one hand, it generates early knowledge of how different products will behave and enables the implementation of corrective actions if productivity or quality issues are detected. Also, it guarantees consistency in product quality across different stages of development, which opens the door to bringing forward development activities that would otherwise be in the critical path for development. Horizon Discovery’s CHOSOURCE™ GS knockout cell line facilitates this by providing optimal performance across the entire discovery-development continuum, as this webinar will demonstrate.
In this GEN Webinar, we will hear about the experience of a scientists working in at Jounce Therapeutics that have integrated the CHOSOURCE platform to build efficiencies across the company’s drug development workflow. Using his own experiences and case studies, our presenter will highlight the benefits of transient and stable transfections of CHO cell lines for various production purposes.
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Product Manager, Bioproduction